A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation
PurposeTheranostics integrates diagnostic imaging (e.g., 18F-PSMA-1007 PET) with targeted radioligand therapy (TRT; e.g., 177Lu-PSMA-617), but personalized dosimetry remains challenging due to complex dose calculations. Current methods like Monte Carlo simulations are accurate but require impractica...
Saved in:
Main Authors: | Thanh Tai Duong, Danny De Sarno, Hatim Fakir, Glenn Bauman, Martin Martinov, Rowan M. Thomson, Ting-Yim Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1600821/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stability in the production and transport of 177Lu labelled PSMA
by: Cristian Antonio Wieczorek Villas Boas, et al.
Published: (2021-03-01) -
Selection and Use of Antioxidants-radioprotectors in the Composition of Therapeutic Radiopharmaceuticals (Review)
by: E. P. Pavlenko, et al.
Published: (2023-12-01) -
LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01) -
Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review
by: Ziye Wang, et al.
Published: (2025-07-01) -
Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617
by: A. A. Larenkov, et al.
Published: (2022-12-01)